深圳微芯生物科技股份有限公司 自愿披露关于公司产品纳入国家医保目录的公告

Group 1 - The company announced that its product, Sidabenamine tablets (Epidaza), has been included in the National Medical Insurance Directory under regular Class B management, effective January 1, 2026 [1][3] - The inclusion of Sidabenamine in the National Medical Insurance Directory is expected to enhance patient access to medication and stabilize the pricing system for innovative drugs [3] - The product is classified under the insurance payment scope for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) and for untreated diffuse large B-cell lymphoma (DLBCL) patients when used in combination with R-CHOP [1][2] Group 2 - Sidabenamine is the world's first subtype-selective histone deacetylase (HDAC) inhibitor and has been approved for various cancers in different regions, including PTCL and DLBCL in mainland China, and adult T-cell leukemia in Japan [2] - The company has pioneered the licensing of innovative drugs from China to Europe and the United States, marking a significant milestone in the industry [2]